Compass Pathways stock climbed 44% following the company's announcement of positive Phase 3 clinical trial outcomes for COMP360, its investigational psilocybin-assisted therapy for treatment-resistant depression. The trial, which enrolled over 1,000 participants, demonstrated statistically significant and clinically meaningful results, marking a significant milestone for the biotech firm's development program.
The London-listed company plans to submit a New Drug Application to the U.S. Food and Drug Administration by the end of 2024, based on the trial data. This regulatory filing represents a critical step toward potential commercialization of the treatment, which addresses a clinical need for patients with depression who have not responded adequately to conventional therapeutic options.
The market reaction reflects investor confidence in the trial's efficacy profile and the accelerated timeline toward regulatory review. The outcome also underscores growing institutional interest in psychedelic-based therapeutics as a treatment category, particularly for conditions with limited alternative options.